Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

AACR 2023 highlights on advances in the treatment of hepatocellular carcinoma with Pierce Chow

Reporting from AACR 2023, Pierce Chow discusses the results of the IMbrave050 trial testing adjuvant atezolizumab plus bevacizumab versus active surveillance in high-risk hepatocellular carcinoma (HCC). This is landmark, the first trial of adjuvant treatment for HCC to show RFS improvement following resection or ablation. Longer follow-up is needed to evaluate if the difference observed in relapse occurrence will translate into a longer survival.

Abstract: CT003 - IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.